Quadria Capital and PE funds reportedly eye majority stake in Samarth Lifesciences at Rs 4500 crore valuation

Published on 24 April 2026

Previous investors walked away over price disagreements

Quadria Capital is reportedly in talks to acquire a majority stake in Samarth Lifesciences, with the deal potentially valuing the company at about Rs 4,500 crore. The pharma firm is seeking fresh investment to support growth plans after earlier negotiations with alternative investors broke down due to mismatches in price expectations.

Quadria Capital reportedly targets a majority stake in Samarth Lifesciences
Potential valuation for the deal is around Rs 4,500 crore
Earlier investment talks stalled over price evaluation gaps
Samarth seeks funding to fuel expansion and growth

#funding #private equity #mergers and acquisitions #pharmaceuticals #quadria capital

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Quadria Capital and PE funds reportedly eye majority stake in Samarth Lifesciences at Rs 4500 crore valuation

The full experience is on mobile.